Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells.

Su JS, Woods SM, Ronen SM.

NMR Biomed. 2012 Feb;25(2):379-88. doi: 10.1002/nbm.1764. Epub 2011 Aug 23.

2.

Perifosine: update on a novel Akt inhibitor.

Gills JJ, Dennis PA.

Curr Oncol Rep. 2009 Mar;11(2):102-10. Review.

PMID:
19216841
3.

Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy.

Sylvester PW, Ayoub NM.

Anticancer Agents Med Chem. 2013 Sep;13(7):1039-47. Review.

PMID:
23272909
4.

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.

Lauring J, Park BH, Wolff AC.

J Natl Compr Canc Netw. 2013 Jun 1;11(6):670-8. Review.

5.

Anticancer mechanisms and clinical application of alkylphospholipids.

van Blitterswijk WJ, Verheij M.

Biochim Biophys Acta. 2013 Mar;1831(3):663-74. doi: 10.1016/j.bbalip.2012.10.008. Epub 2012 Nov 5. Review.

PMID:
23137567
6.

Choline kinase alpha-Putting the ChoK-hold on tumor metabolism.

Arlauckas SP, Popov AV, Delikatny EJ.

Prog Lipid Res. 2016 Jul;63:28-40. doi: 10.1016/j.plipres.2016.03.005. Epub 2016 Apr 9. Review.

7.

Phosphoinositide 3-kinase inhibitors in lymphoma.

Curran E, Smith SM.

Curr Opin Oncol. 2014 Sep;26(5):469-75. doi: 10.1097/CCO.0000000000000113. Review.

8.

Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer.

Iorio E, Caramujo MJ, Cecchetti S, Spadaro F, Carpinelli G, Canese R, Podo F.

Front Oncol. 2016 Sep 30;6:205. eCollection 2016. Review.

9.

Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors.

Sellami D, Dharan B, Wilke C, Scherer SJ, Hirawat S.

Ann Oncol. 2017 Nov 1;28(11):2882-2887. doi: 10.1093/annonc/mdx480. Review. No abstract available.

PMID:
28950291
10.

Choline Metabolism Alteration: A Focus on Ovarian Cancer.

Bagnoli M, Granata A, Nicoletti R, Krishnamachary B, Bhujwalla ZM, Canese R, Podo F, Canevari S, Iorio E, Mezzanzanica D.

Front Oncol. 2016 Jun 22;6:153. doi: 10.3389/fonc.2016.00153. eCollection 2016. Review.

Supplemental Content

Support Center